Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

England’s NHS to offer Lilly’s weight-loss drug to some patients

by Uma Rajagopal
0 comments
2024 10 03T190719Z 2 LYNXMPEK920MB RTROPTP 4 HEALTH OBESITY TELEHEALTH

 

(Reuters) – England’s National Health Services will offer Eli Lilly’s weight-loss drug to nearly a quarter million people as part of a three-year plan, the country’s drugs cost regulator said on Thursday.

The drug, called Mounjaro in the UK and Zepbound in the U.S., would be initially offered to obese people with at least three weight-related health conditions, the National Institute for Health and Care Excellence said.

The conditions are hypertension, sleep apnea, cardiovascular disorders and unhealthy levels of lipids like cholesterol.

As part of a phased rollout, the drug would then be offered to people with two of the conditions and then to those with just one.

The plans have been described in an application from the NHS to UK’s National Institute for Health and Care Excellence.

As part of the plan, the NHS will test several new services to offer the drug, including digital technologies, and will select the most cost-effective one.

NHS plans to offer the drug as part of a “wraparound package”, which will include diet and exercise support through primary or secondary care clinics.

“This is no small task for the NHS, and it will be difficult to provide the level of wraparound care seen in patients who took part in the clinical trial,” said Simon Cork, a physiology lecturer at Anglia Ruskin University.

About 64% of adults are either overweight or living with obesity in England, according to a national survey.

Rival Novo Nordisk’s Wegovy made its weight-loss debut in the UK last year and was also approved in July to reduce risk of serious heart problems or strokes in overweight and obese adults.

The NHS currently offers Wegovy through specialist weight management services.

 

(Reporting by Kashish Tandon in Bengaluru; Editing by Leroy Leo and Arun Koyyur)